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RNA interferenceDespite its considerable interest in human therapy, in vivo siRNA delivery is still suffering from hurdles of
vectorization. We have shown recently efﬁcient gene silencing by non-vectorized cationic siRNA. Here,
we describe the synthesis and in vitro evaluation of new amphiphilic cationic siRNA. C12-, (C12)2- and
cholesteryl–sperminex–siRNA were capable of luciferase knockdown at nanomolar concentrations without
vectorization (i.e. one to two orders of magnitude more potent than commercially available cholesteryl
siRNA). Moreover, incubation in the presence of serum did not impair their efﬁciency. Finally, amphiphilic
cationic siRNA was pre-loaded on albumin. In A549Luc cells in the presence of serum, these siRNA conjugates
were highly effective and had low toxicity.
© 2013 Published by Elsevier B.V.1. Introduction
Since its discovery in 1998 [1], RNA interference has gained tremen-
dous interest because of its ability to knockdown gene expression. Iden-
tiﬁcation of siRNA as key intermediates in such phenomena inmammals
[2] has allowed RNA interference based therapies to reach clinical trials
rapidly [3]. But the two major limitations to in vitro and in vivo use of
siRNA are their lack of chemical and enzymatic stability and their inabil-
ity to enter cells. A wide variety of carriers has thus been developed to
preserve their integrity and transport them into cells. Among them,
synthetic particle-forming vectors: cationic lipids, polymers, dendrimers
or peptides that interact with both anionic nucleic acids and cell mem-
branes have displayed excellent in vitro capacities. Nevertheless, they
face several in vivo limitations, due to their fairly high molecular weight,
including immune response [4,5], non-speciﬁc effects, aggregation on
larger anionic constructs and/or poor tissue diffusion. Normally, delivery
of molecules instead of particles should solve most of these problems.
This can be achieved by chemical siRNA conjugation to residues respon-
sible for their internalization. According to such strategy, siRNA conjuga-
tion to lipidic moieties, polymers or cell-penetrating peptides [6–11]
successfully knocked down gene expression. A cholesteryl derivativeityl; EMAM, ethanolic methyl-
ed laser desorption/ionization
nic acid; ON, oligonucleotide;
leic acid; SDS, sodium dodecyl
monium acetate; TEM, trans-
, tri-isopropyl silyloxymethyl;
: +33 3 68 85 43 06.
sevier B.V.of siRNA is also commercially available, but it contains chemical and
undisclosed modiﬁcations on the nucleic acid backbone and/or phos-
phodiester linkage, and is efﬁcient only at micromolar concentration,
without serum [12]. Moreover, the in vivo effect of siRNA conjugation
was either limited [7] or necessitated high doses [7,9,10].
In our case, oligonucleotide conjugateswere obtained by a stepwise-
automated synthesis developed in our laboratory [13,14]. The repetitive
introduction of a natural polyamine, spermine, at the 5′ end of siRNA
passenger strand resulted in siRNA with an overall cationic charge
[15]. Such conjugates exhibited in vitro carrier free transfection and
gene silencing [15] under serum free conditions. As siRNA backbones
remained chemically unmodiﬁed to prevent any loss of biological activ-
ity or selectivity, and were not protected by a carrier, we anticipated
that siRNA resistance to nucleases would be decreased.
We thus synthesized three lipid-cationic siRNA analogues and
hypothesized that association of the lipidic moiety of cationic siRNA to
serumproteins could providemolecular carriers thatwould enable intra-
venous circulation of siRNA and sterically protect them fromdegradation
bynucleases. As albumin accounts for 60% of humanplasmaproteins and
has already been used as molecular carrier for lipidic siRNA [10], it was
chosen for this study.
We thus report here an in vitro study to compare the efﬁciency of
cationic and lipid-cationic siRNA conjugates, their toxicity, and their
resistance to serum degradation, as well as the impact of siRNA pre-
association to the albumin molecular carrier on their efﬁciency.
2. Materials and methods
All oligonucleotide synthesis reagents and puriﬁcation cartridges
(GlenPak RNA) were purchased from Glen Research/Eurogentec
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which was provided by Carlo Erba-Sds (Val de Reuil, France). DMT-
spermine phosphoramidite was synthesized according to published
procedure [13] and precipitated in pentane. Oligonucleotides and
oligonucleotide conjugates syntheses (1 μmol scale) were performed on
an automated Expedite 8900 Nucleic Acid Synthesis System (GMI Inc.,
USA) with Expedite software, using TOM-protected phosphoramidites,
standard capping reagents (cap Mix A: Ac2O/THF 1:9, Cap mix B: 10%
n-methyl imidazole/THF/Pyridine: 1:8:1), 5-Benzylthio-1H-tetrazole in
acetonitrile as activator and 0.02 M I2 in THF/Pyridine/H2O as oxidizing
solution. Lipidic moieties were introduced with cholesterol TEG or C-
12-spacer phosphoramidites (Glen Research). Coupling yields were
assessed by measuring the absorbance at 504 nm of recovered DMT
fractions diluted in 100 mL 3% TCA/dichloromethane solution on a Cary
100 Bio Spectrophotometer (Varian, Les Ulis, France). Oligonucleotides
were freeze-dried on a Savant SpeedVac concentrator SVC100H(Thermo
Fisher, Illkirch, France). MALDI-TOF mass spectra were obtained in the
positive mode on a Bruker Daltonics (Wissembourg, France) Ultraﬂex
apparatus using hydroxypicolinic acid or trihydroxyacetophenone com-
bined with diammonium citrate as matrix.
2.1. Oligonucleotide synthesis
To obtain oligonucleotide conjugates, standard instrumental proto-
col for a 1 μmol scale RNA synthesis was used with the following mod-
iﬁcations: 1) increased wash volume after TCA deblocking (total
volume of ca. 4 mL) for complete DMT recovery, 2) extended capping
cycle time (3 min), 3) extended spermine coupling cycle (4 min), 4)
extended cholesteryl TEG or C12 spacer coupling time (15 min).
The GL3 siRNA sequence was designed to hybridize to nucleotides
154–172 of the modiﬁed Photinus pyralis ﬁreﬂy luciferase gene
(sequence given in Table 1). All the oligonucleotides were synthesized
with ﬁnal DMT-ON conditions. Average coupling yields were >97%
for nucleotide couplings and >95% for spermine couplings. Oligonucle-
otide cleavage from the support and deprotection were achieved
according to manufacturer's protocol [16], with EMAM deprotection
duration increased up to one night. Oligonucleotide puriﬁcation was
carried out onGlenPakRNA cartridges. The standard protocol underwent
slight modiﬁcations: 1) before oligonucleotide loading onto the column,
1 mL acetonitrile followed by 1 mL TEAA were passed through, 2)
ﬁnal elution was performed by, a) a 70% NH3 (1/20)/30% ACN elution
for CholS30[GL3ss] and (C12)2S30[GL3ss] followed by 2.5 M acetic
acid neutralization (50 μL), b) a 0.07 M NH4CO3/70% ACN elution
for Chol[GL3ss], c) a 0.07 M NH4CO3/70% ACN elution for other sam-
ples. Oligonucleotide-containing fractions were pooled, lyophilisedTable 1
Syntheses yields of sense strands and mass spectrometry data.
Name
(5′-3′)
Sequence (5′-3′) Yield
(nmol)
[MH]+
calc. (Da)
[MH]+
obs. (Da)
S30[GL3ss] S30-CUUACGCUG
AGUACUUCGATT
15 18,863 18,844
CholS30[GL3ss] Chol-S30-CUUACGCU
GAGUACUUCGATT
5 19,619 19,776
C12S30[GL3ss] C12-S30-CUUACGCU
GAGUACUUCGATT
12 19,128 19,194
(C12)2S30[GL3ss] (C12)2-S30-CUUACGC
UGAGUACUUCGATT
4 19,392 19,382
S30[Ctrlss] S30-AUGUCUACUGG
CAGUCCUGTT
16 18,879 19,046
CholS30[Ctrlss] Chol-S30-AUGUCUAC
UGGCAGUCCUGTT
4 19,635 n.d.
C12[GL3ss] C12-CUUACGCUG
AGUACUUCGATT
96 6872 6879
(C12)2[GL3ss] (C12)2-CUUACGCU
GAGUACUUCGATT
117 7136 7148
Chol[GL3ss] Chol-CUUACGCUG
AGUACUUCGATT
17 7364 7372on a Speed Vac concentrator, dissolved in RNAse-free water (Qiagen,
Hilden, Germany) and stored at −20 °C. Neither precipitation nor ag-
gregationwas seen during the freeze-drying process. Naked oligonucle-
otides GL3as and GL3ss were purchased from Eurogentec.
Overall yields listed in Table 1 were calculated from the ﬁnal stock
solutions concentrations by measurement of their 260 nm absorption
[13].
2.2. Duplex hybridization
Following RNA strandswere annealed in RNAse-freewater by heating
2 min at 94 °C followed by slow cooling: S30GL3, CholS30GL3, C12S30GL3,
(C12)2S30GL3, S30Ctrl, CholS30Ctrl, CholGL3, C12GL3, (C12)2GL3 and GL3.
The Ctrl siRNA sequence was described as universal negative control
designed for use in Human, Mouse or Rat cells. The ﬁnal concentration
of all siRNA stock solutions was 20 μM.
2.3. Gel electrophoresis analysis
RNA oligonucleotide conjugates and related duplexes hybridized
as above were analysed by migration of 200 pmol single and double
stranded RNA mixed with 1/25th diluted Laemmli buffer, at 120 V
for 90 min. The gel electrophoresis was achieved through a NuPAGE
4–12% gradient Bis-Tris denaturating gel on a XCell Sure Lock™
Mini-Cell apparatus (Invitrogen, Carlsbad, CA, USA) with MOPS-SDS
1× as running buffer. Oligospermine–oligonucleotide conjugates
and siRNA duplexes were visualized by UV shadowing.
2.4. Transmission electron microscopy (TEM)
Ten microliters of siRNA duplex samples were transferred onto
300 mesh formvar-coated copper grids for 1 min (Ted Pella, Redding,
CA, USA). Grids with adherent samples were wicked from one side,
placed for 30 s on a 50 μL drop of 2% uranyl acetate, wicked again
and air dried. Images were taken with a TEM Philips CN12 apparatus.
2.5. Cell culture
A549Luc cells stably expressing large amounts of luciferase GL3
((1–2) × 1010 RLU/mg protein) were obtained by transfecting human
lung carcinoma A549 cells (CCL-185; ATCC) with pGL3Luc plasmid
(Clontech, Mountain View, CA, USA) using jetPEI™ as delivery system
(Polyplus-Transfection, Illkirch, France). Cells were grown in RPMI
1640 medium (Eurobio, Les Ulis, France) supplemented with 10% FBS
(Perbio, Brebieres, France), 2 mM L-glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin (Eurobio) and maintained under 0.8 μg/mL
G418 selection (Promega, Madison, WI, USA) at 37 °C in a 5% CO2
humidiﬁed atmosphere.
2.6. Transfection with oligospermine–oligonucleotide conjugates
Twenty-four hours prior to transfection, 2.5 × 104 A549 Luc cells
were seeded per well in 24-well tissue culture plates (Corning, NY,
USA). The required amounts of cationic or lipophilic cationic siRNA
duplexes were diluted up to 100 μL in serum-free OPTI-MEM (Gibco,
Grand Island, NY, USA) or in a ﬁltered solution of bovine serumalbumin
(Sigma, St. Louis,MO,USA) atﬁnal concentration of 20 mg/mL complet-
ed with OPTI-MEM. In the latter case, samples weremixed and incubat-
ed 40 min at room temperature to favour association between cationic
siRNA and albumin. Target or control siRNA conjugated with 30
spermines units prepared in OPTI-MEM or OPTI-MEM-albumin were
then added onto the cells in the presence (10%) or absence of
serum in 0.5 mL RPMI 1640 medium. After 4 h of incubation, the
ﬁnal volume was completed to 1 mL with medium to obtain 10%
serum concentration. For positive controls, cells were transfected
with 10 nM of speciﬁc GL3 siRNA and lipophilic GL3 siRNA vectorized
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according to the supplier recommendations. All experiments were
done in triplicate.
2.7. Quantiﬁcation of the luciferase gene silencing
Luciferase gene expression was determined 48 h after delivery with
a Luciferase Assay System (Promega, Charbonnières, France) according
to manufacturer's instructions. The luminescence was quantiﬁed from
2 μL of cell lysate with a Centro LB luminometer (Berthold, Thoiry,
France). Protein concentration in cell lysate was measured by using a
BCA assay kit (Interchim, Montluçon, France), according to
manufacturer's instructions. After expressing the luciferase activity as
relative light units integrated over 10 s per mg of cell protein (RLU/
mg), the luciferase gene silencing was calculated relative to the lucifer-
ase activity of non-transfected A549Luc cells.
3. Results
In this report, three different lipids were conjugated to cationic
oligonucleotides: a cholesterol moiety and two aliphatic chains bearing
12 or 24 carbons (Fig. 1).
Following a previous study [15], we used a 19-nt long sequencewith
2 dT overhangs: theGL3 sequence targetingﬁreﬂy luciferase gene. Like-
wise, 30 spermines were coupled to afford siRNA optimum transfection
and activity.
Subsequently to RNA synthesis, spermine and lipid phosphoramidites
were conjugated with high yields (≥95%) with minor changes of usual
coupling cycle. After deprotection and puriﬁcation on afﬁnity chromatog-
raphy cartridges with slightly improved protocols, lipophilic cationicFig. 1. Cationic oligonucleotide and lipophilic derivatives.oligonucleotides conjugates and related controls were ﬁrstly character-
ized by mass spectroscopy (see SI), then by SDS–PAGE. Both single
stranded RNA and hybridized RNAswere analysed by gel electrophoresis,
in experimental conditions generally used for protein analysis
(denaturating gel), with UV shadowing (Fig. 2).
Single stranded RNA without spermines appeared near or with the
migration front (bottom), while spermine-containing oligonucleo-
tides were much more retarded on the gel (top). Formation of
spermine-containing duplexes was conﬁrmed by the slight shift
(higher retardation) observed between single-strand (lanes a, c, e,
and g) and duplex bands (lanes b, d, f, and h). Control oligonucleo-
tides (without spermines) were also migrating near/with the migra-
tion front (i-l). Control CholGL3 (k) was more retarded on the gel
than other related controls.
TEM experiments further characterized cationic siRNA and their
lipophilic counterparts. At 100 nM, S30GL3 exhibited mostly 4–6 nm
spots (indicated by black arrows, Fig. 3a) thatmight correspond to indi-
vidual or very few siRNA molecules, as controls did not show the same
structures (data not shown).
Some of the material also appeared as particles of 20 nm, along with
fewhigher size granular particles of 60 nm, showing the ability of cation-
ic siRNA to self-assemble. CholS30GL3 displayed structures clearly remi-
niscent of tubular micelles (Fig. 3b) along with few higher size particles
(Fig. 3b inset). CholS30GL3 oblong structures argue in the favour of a
dynamic system [17]. Out of the four cationic siRNA, C12S30GL3 showed
the highest percentage of large granular particles with 15–20 nm and
40–50 nm populations (Fig. 3c). (C12)2S30GL3 showed mostly round
shaped micellar structures along with 25 nm granular particles
(Fig. 3d). All compounds were incubated for 30 min with 20 mg/mL
(ca. one thousand molar equivalents) albumin before observation by
TEM. None of the previously described structures were visible, whereas
at lower albumin concentration (0.1 mg/mL) they were still present
(data not shown). These observations strongly suggest the association
of oligonucleotides and albumin, and therefore the disappearance of
micellar structures.
Human lung cells A549Luc were used to assess RNA interfer-
ence efﬁciency. This cell line stably and highly expresses luciferase
([1–2] × 1010 RLU/mg protein). Luciferase gene expression knockdown
was observed after 48 h of siRNA incubation, by luminescence measure-
ment. Optimal time-frame for luciferase knock-downmeasurement was
found to be between 30 to 80 h post-transfection (data not shown).
Forty-eight hours of incubation were therefore used, in accordance to
what is usually found in the literature. Toxicity was evaluated by cellular
proteinmeasurement. Unless otherwise stated, all siRNAwere deposited
on cells without transfection agent.
Initial experiments were carried out under serum free conditions:
cells were supplemented with serum 4 h after siRNA addition (with-
out removal of the ON). First, the optimum concentration for siRNA
activity was determined (Fig. 4). It has to be noticed that we did not
consider silencing ≤70% to be biologically relevant (hatched line).
At 100 and 50 nM, self-penetrating cationic siRNA inhibited luciferase
expression at 90 and 80%, respectively. RNA interference was totally
abolished at 10 nM. Strong toxicity was visible at 100 nM and detect-
able at 50 nM.Fig. 2. PAGE analysis. Oligonucleotides inside brackets are single stranded a. C12S30
[GL3ss], b. C12S30GL3, c. CholS30[GL3ss], d. CholS30GL3, e. S30[GL3ss], f. S30GL3, g.
(C12)2S30[GL3ss], h. (C12)2S30GL3, i. [GL3as], j. C12[GL3ss], k. Chol[GL3ss], l. (C12)2[GL3ss].
Fig. 3. Transmission electron micrographs: a. S30GL3; b. CholS30GL3; c. C12S30GL3; d. (C12)2S30GL3.
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S30GL3. At 100 nM, only 82% (CholS30GL3) down to 70% (C12S30GL3 and
(C12)2S30GL3) gene silencing was obtained. Moreover, neglectable silenc-
ingwas obtained at 50 nM. However, cell viabilitywas strongly increased
for all lipophilic conjugates (≥90% of cell proteins). Control anionic siRNA
conjugated to lipidic moieties displayed no activity at 100 nM, and even
at doses as high as 500 nM (data not shown), but were able to knock-
down gene expression when transfected by Interferin™ (10 nM).
To test the inﬂuence of albumin as amolecular carrier on the efﬁciency
and toxicity of siRNA derivatives, lipophilic cationic siRNA and controls
were pre-incubated with excess albumin (20 mg/mL) for 40 min before
addition onto cells, in serum-free conditions (Fig. 5). In almost all
conditions, albumin did not modify signiﬁcantly the efﬁciency and toxic-
ity of siRNA. Only CholS30GL3 and (C12)2S30GL3were slightly inhibited by
albumin.
Finally, both free and albumin preloaded lipophilic cationic siRNA
were tested in the presence of serum (Fig. 6).
Strikingly, except for CholS30GL3, albumin-free lipophilic cationic
siRNA and cationic siRNA were still capable of ca. 90% of luciferase
expression knockdown for concentrations only twice as high as in the
absence of serum: 100 nM for S30GL3 and 200 nM for (C12)2S30GL3 and
C12S30GL3, respectively. Surprisingly, CholS30GL3 reminiscent of the com-
mercially available Accellmolecule (Dharmacon) is not able to inhibit sig-
niﬁcantly luciferase expression at the concentrations that were tested.
Here again, high concentration of albumin did not interfere with siRNA
delivery.4. Discussion
For gene silencing, only the antisense lead strand [18] is used by
the RISC complex to screen mRNAs and cleave its target. Thus, to en-
sure no off-target effects due to spermine or lipid conjugation, and as
intact 5′ antisense position is crucial to maintain RNA interference
[19], conjugations were made on the 5′ end of passenger sense strand.
Moreover, addition of spermines should increase the stability of the
corresponding end of the siRNA duplex and consequently guide the
enzymatic complex RISC towards antisense strand selection [20,21].
Nuclease resistance can be obtained by chemically modifying the
nucleic acid backbone. However, chemical modiﬁcations can also in-
duce reduced efﬁcacy and/or selectivity [22]. For these reasons, siRNA
backbone was kept “natural.” The oligospermine tail may also protect
the siRNA from nuclease degradations, by folding back on the ON back-
bone, through electrostatic interactions. Another possible way to in-
crease steric hindrance towards nucleases would be to dock cationic
siRNA on a protein. As albumin is the major constituent of serum pro-
teins, and has already been used as a carrier for lipophilic drugs and
nucleic acids, we synthesized three hydrophobic derivatives of cationic
siRNA, containing a C12, a (C12)2, or a cholesteryl moiety. Cholesteryl
siRNA derivatives are already commercially available, but together
with undocumented chemical modiﬁcations of the siRNA backbone. As-
sociation (docking) of lipophilic siRNA on albumin should ensure a bet-
ter protection and biodistribution in the case of intravenous delivery
[23].
140120100806040200
%
Interferin GL3
S30 GL3 100 nM
50 nM
10 nM
S30 CTrl 100 nM
Interferin CholGL3
CholS30 GL3 100 nM
50 nM
10 nM
CholS30 Ctrl 100 nM
Interferin C 12 GL3
C12S30 GL3 100 nM
50 nM
10 nM
Interferin (C 12 )2 GL3
(C12 )2S30 GL3 100 nM
50 nM
10 nM
Fig. 4. Concentration dependence of siRNA activity under serum free conditions. Percentage of luciferase expression (bars) and cellular proteins (dots) vs. untreated cells. Means
and error bars are given.
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prepared by standard phosphoramidite chemistry. However these syn-
theses suffer from overall low yields, even after optimization of the cou-
pling conditions (>95% average yield). Prolonged coupling time and/or
repeated couplings did not further improve the efﬁciency. Moreover, a
considerable part of the material was lost during puriﬁcation on
reverse-phase cartridge. Characterization of these ONs was done by40200
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Fig. 5. Inﬂuence of albumin on siRNA efﬁciency and toxicity without serum. Percentage of lu
are given.MALDI-TOF affording usually the expected mass peak within ±100 Da
(see SI, less than 0.5% relative error) using hydroxypicolinic acid or
trihydroxyacetophenone combinedwith diammonium citrate as matrix.
It is difﬁcult to observe well-resolved peak when ONs are conjugated to
30 spermines.With CholS30 [GL3], only aweak peakwas observed,while
the mass peak of CholS30[Ctrl] was not detected in these conditions. The
C12- and (C12)2-S30-ODNs afforded clearly themass peaks. The other lipid1401201008060
%
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Fig. 6. Lipophilic cationic siRNA activities in the presence of serum ± albumin. Percentage of luciferase expression (bars) and cellular proteins vs. untreated cells. Means and error
bars are given.
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adducts (Na, K).
Spermine-coupled ONs did not properly migrate in regular agarose
or polyacrylamide gel electrophoresis conditions, most probably due to
their zwitterionic nature and overall net cationic charge. However,
the experimental setup designed for protein electrophoresis (i.e.MOPS-
SDS, and Bis-Tris gradient), allowed differential migration of ONs. SDS
probably interacts electrostatically with the cationic oligo-spermine tail,
leading to charge shielding and even reversal. Therefore, electrophoretic
mobility is related to the size/molecular weight and charge of the ON de-
rivatives, inducing differential migration of spermine-modiﬁed- vs.
natural ONs. Only gradient gels allowed the migration of modiﬁed and
unmodiﬁed ONs on the same gel. PAGE experiment showed contamina-
tion of spermine-coupled oligonucleotides byONs bearing no spermines.
The absence of a corresponding molecular peak in MALDI-TOF data
(see SI) leads us to hypothesize that electrophoresis conditions are
breaking the bond between the ﬁrst spermine and the last nucleo-
tide by an unknown mechanism, and is not reﬂecting the actual pu-
rity of spermine-ONs and their lipophilic derivatives. However, the
smears that appear in various bands may reﬂect some degradation of
ONs. Only CholS30GL3 single and double stranded ONs clearly exhibited
a different migration proﬁle that could be due to the formation of
multimeric species, due to the highly hydrophobic cholesteryl moiety.
All cationic ONs were visualized as nanometric structures, ranging
from quasi-monomolecular (S30GL3) to spherical micelles of less than
50 nm, at the exception of the cholesteryl derivative, that was seen as
oblong and interlaced micelles. As cationic siRNA and their lipophilic
analogues have natural RNA backbones, stability towards serum nucle-
ases and proteins might arise from their ability to form self-assemblies
that could protect the genetic material. Alternatively, spermine moiety
could fold backwards into the double stranded siRNA. Disappearance
of the micelles in the presence of albumin indicates that ionic and Van
der Waals interactions with serum protein disrupted the micelles and
efﬁciently loaded lipophilic and/or cationic ONs on proteins. Therefore,
albumin can be considered as a carrier for these nucleic acids.
All cationic siRNA successfully inhibited luciferase expression in
vitro, at 100 nM in serum-free conditions. One should emphasize thatthese results were obtained with single molecules (or aggregates of
fewmolecules), as opposed to “large” particles obtained with synthetic
vectors, that sediment (therefore concentrate) onto cells during trans-
fection. Cholesteryl cationic siRNA compares favorably with Accell
siRNA, as the manufacturer protocols recommends to work at 1 μM.
Negative controls were composed of an irrelevant siRNA sequence
coupled to 30 spermines and anionic lipophilic siRNA directed against
luciferase (data not shown). None of themwas able to silence luciferase
expression. At the opposite, vectorization by Interferin™ of lipophilic
siRNAdirected against luciferasewas able to knock down>80% of lucif-
erase expression, showing little (CholGL3) if not no inﬂuence of the
chemical modiﬁcations on biological activity.
As shown by TEM imaging, addition of albumin to cationic siRNA
(hydrophilic and lipophilic) led to micelle/aggregate disruption, show-
ing the ionic and/or Van der Waals interactions between them. siRNA
was therefore pre-mixed with concentrated albumin prior to transfec-
tion. For half of themolecules (CholS30GL3 and (C12)2S30GL3), efﬁciency
was reduced,whereas for C12S30GL3 and S30GL3, itwas slightly increased
(at 100 nM). Reasons for this opposite behavior are unknown.
In the presence of 10% serum, albumin only interferedwith vectorized
siRNA,while cationic siRNAwasunaffected. The combined effect of serum
and albumin probably led to lipid/siRNA particle dismantling. What is
more, all but CholS30GL3 derivatives remained highly efﬁcient although
a two-fold increase in concentrations was necessary (C12S30GL3 and
(C12)2S30GL3). In particular, C12S30GL3 combined high efﬁciency and
relatively low toxicity. It is the ﬁrst report of more than 90% expression
knockdown with non-vectorized siRNA, in 10% serum-containing medi-
um. This is achieved by both C12S30GL3 and S30GL3, at 200 nM and
100 nM, respectively.
5. Conclusion
We successfully synthesized three lipophilic cationic siRNA that
exhibited similar in vitro activities than their cationic siRNA precur-
sor. We showed that lipidic cationic siRNA and their cationic counter-
part were resistant to serum at doses comprised between 100 nM
and 200 nM, which is promising for further in vivo study. As lipidic
98 P. Perche et al. / Journal of Controlled Release 170 (2013) 92–98
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Ymoieties were added to serve as anchors on serum proteins for in vivo
use, we studied the effect of a potential molecular vehicle, albumin,
and demonstrated that its presence did neither affect efﬁciencies nor
toxicities of C12S30GL3 and S30GL3 conjugates. Further in vivo study by
intravenous injections of these cationic siRNApreloaded on serum albu-
min to form furtive assemblies and enhance siRNA resistance and diffu-
sion should support the pertinence of our approach [23].
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